Kimberly-Clark is making a big move with a nearly $50 billion acquisition. The North Texas company plans to acquire Kenvue Inc., a personal care product...
The North Texas company plans to acquire Kenvue Inc., a personal care product provider with brands like Tylenol, in a deal that values the target at about $48.7 billion,Kimberly-Clark’s lineup includes Huggies, Kleenex and Kotex while Kenvue covers names such as Aveeno, Band-Aid, Listerine and Neutrogena.
The deal will bring together products “that touch nearly half the global population through every stage of life,” the statement said.“Over the last several years, Kimberly-Clark has undertaken a significant transformation to pivot our portfolio to higher-growth, higher-margin businesses while rewiring our organization to work smarter and faster,” Mike Hsu, Kimberly-Clark CEO, said in the statement. “We have built the foundation and this transaction is a powerful next step in our journey.”The combined businesses would generate 2025 annual net revenue of about $32 billion and approximately $7 billion of adjusted EBITDA.As part of the transaction, Kimberly-Clark has received committed financing from JPMorgan Chase Bank and intends to fund the cash component of the transaction consideration through a combination of cash from its balance sheet, proceeds from new debt issuance and proceeds from the previously announced sale of a 51% interest in its International Family Care and Professional business.What to know about Plano’s Shops at Willow Bend, Dallas Stars’ potential new arena siteBrian is a business reporter specializing in retail for the Dallas Morning News. He earlier covered technology for the Dallas Business Journal after working at other news providers in California, Ohio and Idaho. He now resides in Frisco.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Kimberly-Clark buying Tylenol maker Kenvue in $48.7 billion dealKimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.
Read more »
Kimberly-Clark buying Tylenol maker Kenvue in $48.7 billion dealKimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company.
Read more »
Kimberly-Clark buying Tylenol maker Kenvue in $48.7 billion dealKimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company.
Read more »
Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion dealKimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company.
Read more »
Kimberly-Clark buying Tylenol maker Kenvue in $48.7 billion dealKimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company.
Read more »
Kimberly-Clark buying Tylenol maker Kenvue in $48.7 billion dealKimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.
Read more »